We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Genetic Testing Could Improve Treatment for Virulent Multidrug-Resistant Fungus Candida Auris

By LabMedica International staff writers
Posted on 07 Jan 2025

Candida auris (C. More...

auris), a multidrug-resistant yeast responsible for severe, life-threatening infections, was first identified in 2009. Since its discovery, it has spread globally, causing significant illness in healthcare settings. With a mortality rate estimated between 30% and 60%, C. auris is not only deadly but also difficult to treat. One of the challenges in managing C. auris infections is the existence of various strains, each with distinct genetic characteristics that confer resistance to different antifungal medications. To identify which drugs are effective against a specific strain, clinical laboratories perform susceptibility testing. This process involves growing a sample of the patient’s C. auris alongside different antifungal drugs to observe which one effectively kills the fungus. However, interpreting these test results can be challenging, as minimum inhibitory concentration (MIC) breakpoints—the lowest concentrations of antifungal drugs that stop C. auris growth—have not been fully defined. Consequently, healthcare providers often face delays in selecting the appropriate antifungal treatment, and such delays can be critical, potentially affecting patient outcomes.

Now, a new study published in ADLM's Clinical Chemistry journal, suggests that genetic testing could provide a faster, more accurate way to identify which antifungal drugs will be effective against C. auris infections. The researchers believe that genetic testing could help doctors initiate the right treatment sooner, improving patient outcomes. To explore this possibility, researchers from Columbia University Irving Medical Center (New York City, NY, USA) examined antifungal resistance genes in C. auris samples from 66 patients. These samples were subjected to two types of genetic analysis: whole-genome sequencing (WGS) and Sanger sequencing. These techniques helped identify each strain’s genetic profile. In addition, the samples underwent traditional susceptibility testing, where they were exposed to seven major antifungal drugs.

By comparing the genetic data with the susceptibility test results, the researchers identified several mutations in the FKS1 gene of C. auris that are responsible for resistance to echinocandins, the primary class of antifungal drugs used to treat invasive C. auris infections. Specifically, they discovered that the Ser639Tyr and Arg135Ser mutations in the FKS1 gene are linked to resistance to micafungin and anidulafungin, while the Met690Ile mutation confers resistance to caspofungin. These findings demonstrate that genomic sequencing can pinpoint which drugs a particular strain of C. auris is resistant to, potentially offering an alternative to traditional susceptibility testing.

“With potential resistance to all three major antifungal classes of drugs, C. auris is an emerging public health threat. Early detection of echinocandin resistance by molecular methods could impact treatment course to include novel antifungal agents,” said Dr. Marie C. Smithgall who led the research team. “Overall WGS serves as a powerful tool for molecular surveillance to help monitor, detect, and curb the spread of C. auris.”


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Collection and Transport System
PurSafe Plus®
New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
New
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Pathology

view channel
Image: Erythrocyte Sedimentation Rate Sample Stability (Photo courtesy of ALCOR Scientific)

ESR Testing Breakthrough Extends Blood Sample Stability from 4 to 28 Hours

Erythrocyte sedimentation rate (ESR) is one of the most widely ordered blood tests worldwide, helping clinicians detect and monitor infections, autoimmune conditions, cancers, and other diseases.... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.